abstract: Isoniazid is an efficacious treatment for @entity6 . Concerns remain, however, regarding hepatotoxicity associated with this medication. In addition, adherence may be suboptimal because at least 6 months of treatment is required. We extracted information from our @entity6 treatment database to determine adverse effects and treatment completion rates associated with the use of @entity5 at a county @entity4 clinic. Outcomes were available for 3,788 @entity0 started on isoniazid between 1999 and 2002. Six hundred seventy-two @entity0 (18%) experienced one or more adverse effects, including 10 (0.3%) determined to have isoniazid-associated @entity1 . No hospitalizations or @entity3 occurred in @entity0 experiencing an adverse effect. A higher incidence of adverse effects was associated with increasing age. Sixty-four percent of @entity0 completed at least 6 months of isoniazid. Higher completion rates were associated with younger age, Hispanic ethnicity, and non-U.S. country of birth. Lower completion rates were associated with being homelessness, using excess @entity2 , and having experienced an adverse effect. In summary, we conclude that in our clinic population isoniazid is a safe therapy for @entity6 , but its effectiveness is limited by modest completion rates.

title: Use of isoniazid for latent XXXX in a public health clinic.

answer: @entity4


abstract: @entity0 were treated with @entity6 ( @entity6 ) acutely or daily for 14 days. The involvement of various presynaptic and postsynaptic functions of the cholinergic system in the development of tolerance to DFP was studied. Receptor density and affinity of both muscarinic and nicotinic receptors, high-affinity @entity4 uptake, and [K+]-evoked release of @entity1 ( @entity3 ) by @entity5 were not changed after acute administration of 2 mg/kg DFP. Both muscarinic and nicotinic receptors were down-regulated to the same extent (40-50%) after subacute administration of DFP (1 mg/kg) without changes in their affinities. Binding sites of muscarinic receptors were maximally decreased after 7 days of DFP administration. Thereafter, they remained constant throughout 14 days of administration. One hour after the last injection of 2 mg/kg DFP to subacutely treated @entity0 , the maximum velocity of high-affinity @entity4 uptake was significantly decreased in the striatum (33%) and hippocampus (53%) without changes in Km values. Twenty-four hours after the last injection of DFP, only a higher dose of DFP (2 mg/kg) significantly inhibited @entity4 uptake. @entity2 -evoked release of @entity3 by slices of striatum was not different between acutely and subacutely treated @entity0 . However, the release of @entity3 by slices of striatum and hippocampus was significantly increased by @entity5 in subacutely treated @entity0 . It is suggested that along with the down-regulation of the postsynaptic receptors, subsensitivity of presynaptic functions of the cholinergic synapse also develops during subacute administration of DFP.

title: Evidence for the involvement of presynaptic cholinergic functions in tolerance to XXXX .

answer: @entity6


abstract: OBJECTIVE: One of the hemodynamic consequences of @entity2 is pressure overload leading to left @entity1 . Left atrial size is a known risk factor providing prognostic information in several cardiac conditions. It is not known if this is also the case in @entity0 with @entity2 after aortic valve replacement. METHODS: A total of 119 @entity0 with severe @entity2 scheduled for aortic valve replacement were evaluated preoperatively and divided into 2 groups according to left atrial volume index (>= 40 mL/m(2)). Echocardiography was repeated 12 months after surgery. @entity0 were followed up for 24 months. The primary end point was the composite end point overall mortality and hospitalization due to @entity3 . RESULTS: Preoperative left atrial dilation was associated with @entity4 and increased filling pressure. Preoperative left atrial volume index was associated with persistent abnormalities in left ventricular filling pressure and left ventricular mass index at 1 year after surgery. Event-free survival in @entity0 with left atrial volume index of 40 mL/m(2) or more at 1 year was 71% compared with 88% in @entity0 with left atrial volume index less than 40 mL/m(2) (P = .002). @entity0 with preoperative increased E/e' ratio and @entity4 were at increased risk. In Cox regression analysis after correcting for standard risk factors, left atrial volume index was found to be the only significant predictor of the composite end point. In a forward conditional multivariable model, left atrial volume index 40 mL/m(2) or greater (hazard ratio, 4.2 [1.6-10.7]; P = .003) remained an independent predictor, whereas E/e' was borderline significant (P = .06). CONCLUSIONS: In @entity0 with symptomatic severe @entity2 undergoing aortic valve replacement, left atrial volume provides important prognostic information beyond standard risk factors.

title: Noninvasive assessment of filling pressure and left atrial pressure overload in severe XXXX : relation to ventricular remodeling and clinical outcome after aortic valve replacement.

answer: @entity2


abstract: UNASSIGNED: @entity6 ( @entity6 ) achieve an intermediate or primed state of activation following stimulation with certain agonists. Primed @entity6 have enhanced responsiveness to subsequent stimuli, which can be beneficial in eliminating microbes but may cause host tissue damage in certain disease contexts, including @entity2 . As @entity6 priming by @entity5 agonists is well described, we hypothesized that ligation of @entity9 or @entity4 /6 would prime @entity6 . Surprisingly, @entity6 from only a subset of donors were primed in response to the @entity9 agonist, Pam3CSK4, although @entity6 from all donors were primed by the @entity10 agonist, @entity11 . Priming responses included generation of intracellular and extracellular reactive @entity1 species, MAPK phosphorylation, integrin activation, secondary granule exocytosis, and cytokine secretion. Genotyping studies revealed that @entity6 responsiveness to Pam3CSK4 was enhanced by a common single-nucleotide polymorphism (SNP) in @entity7 ( @entity12 ). Notably, @entity6 from donors with the SNP had higher surface levels of @entity7 and were demonstrated to have enhanced association of @entity7 with the endoplasmic reticulum chaperone @entity8 . We analyzed @entity7 genotypes in a pediatric @entity2 database and found that @entity0 with @entity2 or @entity3 who had a positive blood culture and were homozygous for the SNP associated with neutrophil priming had prolonged pediatric intensive care unit length of stay. We conclude that this @entity7 SNP leads to excessive @entity6 priming in response to cell stimulation. Based on our finding that septic @entity0 with this SNP had longer pediatric intensive care unit stays, we speculate that this SNP results in hyperinflammation in diseases such as @entity2 .

title: A Common Genetic Variant in XXXX Enhances @entity0 Neutrophil Priming and Impacts Length of Intensive Care Stay in Pediatric Sepsis.

answer: @entity7


abstract: UNASSIGNED: @entity6 ( @entity6 ) achieve an intermediate or primed state of activation following stimulation with certain agonists. Primed @entity6 have enhanced responsiveness to subsequent stimuli, which can be beneficial in eliminating microbes but may cause host tissue damage in certain disease contexts, including @entity2 . As @entity6 priming by @entity5 agonists is well described, we hypothesized that ligation of @entity9 or @entity4 /6 would prime @entity6 . Surprisingly, @entity6 from only a subset of donors were primed in response to the @entity9 agonist, Pam3CSK4, although @entity6 from all donors were primed by the @entity10 agonist, @entity11 . Priming responses included generation of intracellular and extracellular reactive @entity1 species, MAPK phosphorylation, integrin activation, secondary granule exocytosis, and cytokine secretion. Genotyping studies revealed that @entity6 responsiveness to Pam3CSK4 was enhanced by a common single-nucleotide polymorphism (SNP) in @entity7 ( @entity12 ). Notably, @entity6 from donors with the SNP had higher surface levels of @entity7 and were demonstrated to have enhanced association of @entity7 with the endoplasmic reticulum chaperone @entity8 . We analyzed @entity7 genotypes in a pediatric @entity2 database and found that @entity0 with @entity2 or @entity3 who had a positive blood culture and were homozygous for the SNP associated with neutrophil priming had prolonged pediatric intensive care unit length of stay. We conclude that this @entity7 SNP leads to excessive @entity6 priming in response to cell stimulation. Based on our finding that septic @entity0 with this SNP had longer pediatric intensive care unit stays, we speculate that this SNP results in hyperinflammation in diseases such as @entity2 .

title: A Common Genetic Variant in @entity7 Enhances XXXX Neutrophil Priming and Impacts Length of Intensive Care Stay in Pediatric Sepsis.

answer: @entity0


abstract: UNASSIGNED: @entity1 , @entity0 ( @entity0 ) in particular is a global problem and big threat to the aging population. An image based computer-aided @entity1 diagnosis method is needed to providing doctors help during medical image examination. Many machine learning based @entity1 classification methods using medical imaging have been proposed and most of them achieve accurate results. However, most of these methods make use of supervised learning requiring fully labeled image dataset, which usually is not practical in real clinical environment. Using large amount of unlabeled images can improve the @entity1 classification performance. In this study we propose a new semi-supervised @entity1 classification method based on random manifold learning with affinity regularization. Three groups of spatial features are extracted from positron emission tomography (PET) images to construct an unsupervised random forest which is then used to regularize the manifold learning objective function. The proposed method, stat-of-the-art Laplacian support vector machine (LapSVM) and supervised SVM are applied to classify @entity0 and normal controls (NC). The experiment results show that learning with unlabeled images indeed improves the classification performance. And our method outperforms LapSVM on the same dataset.

title: Semi-supervised manifold learning with affinity regularization for XXXX identification using positron emission tomography imaging.

answer: @entity0


abstract: BACKGROUND: @entity4 @entity0 who underwent Heller cardiomyotomy with Toupet's fundoplication have excellent results in a previous report data. However, the result with open technique has not been reported in Thai. OBJECTIVE: To study the immediate and long-term outcome of open transabdominal Heller cardiomyotomy with Toupet's fundoplication in @entity4 @entity0 . MATERIAL AND METHOD: Retrospective review of all @entity4 @entity0 who underwent open Heller cardiomyotomy with Toupet's fundoplication in Maharaj Nakorn Chiang Mai Hospital, Thailand during the past ten years (1997-2007). The data was analysis with descriptive statistics. RESULTS: Twenty-two cases (11 male) were included in this study. Mean age was 40 years. The mean duration of symptoms before surgery was 62.5 months. Ninety-one percent of @entity0 were free from @entity3 immediately after operation. There was no early @entity2 . Three @entity0 had relapse symptom (14%). Mean follow-up time in the present study was 30 months. CONCLUSION: Open @entity1 with augmented Toupet's fundoplication done by experienced surgeons is an effective technique to treat @entity4 @entity0 in our center.

title: XXXX with augmented Toupet's fundoplication immediate and long-term outcome.

answer: @entity1


abstract: PURPOSE: The current study evaluates the feasibility and safety of coil embolisation of the anterior communicating artery (ACoA) for the treatment of complicated anterior communicating @entity2 (ACoAAs). METHODS AND MATERIALS: Five @entity0 presented with a @entity4 caused by a ruptured ACoAA. The ACoAA morphologies were well defined by three-dimensional digital subtraction angiography (3D-DSA) and magnetic resonance angiography (MRA). Two of the ACoAAs were tiny (<3   mm in diameter), and the remaining three ACoAAs were small (3-5   mm in diameter). All of the @entity3 were localised to the ACoA. The projection of the @entity3 dome was defined as being oriented superiorly or posteriorly in all five @entity3 . We performed a superselective catheterisation of each @entity3 , and we subsequently performed coil embolisation with balloon, stent or microcatheter assistance. Angiography and clinical follow-up occurred 3-6 months after the procedure. Clinical follow-up data were collected and retrospectively analysed, and @entity0 responses were categorised as fully recovered, improved, unchanged or aggravated. RESULTS: All five @entity0 with ACoAA were treated successfully using coil embolisation. In three @entity0 , both the @entity3 sac and the ACoA were embolised using coils, and in two @entity0 , only the ACoA was embolised. Acute angiography showed occlusion of the @entity3 and ACoA. Follow-up angiography confirmed complete occlusion of the @entity3 sac, and no ACoAA recurrence was detected in any of the @entity0 . In clinical follow-up visits, none of the @entity0 had @entity5 or had a @entity1 . CONCLUSION: Combined coil embolism of the @entity3 sac and the ACoA could be a feasible and safe method for the treatment of complicated ACoAAs without bilateral aplasia of the A1 segment.

title: Treatment of complex ruptured anterior communicating XXXX by endovascular coil embolisation of the anterior communicating artery.

answer: @entity2


abstract: @entity6 ( @entity6 ) is an @entity5 that is characterized by the specific destruction of insulin-producing pancreatic b cells. Invariant natural killer T (iNKT) cells have been associated with development of @entity6 . @entity8 ( @entity8 ) is expressed on activated iNKT, @entity4 (+), and @entity3 (+) T cells, and it is associated with the pro-inflammatory profiles of these cells. @entity9 gene expression in @entity7 (+) lymphocytes from non-obese @entity1 (NOD) @entity2 is associated with @entity6 onset. However, expression of @entity8 on T cells from @entity0 with @entity6 has not yet been evaluated. We compared iNKT cell ( @entity7 (+)Va24(+)Vb11(+)) numbers and @entity8 expression in a Mexican population with recent-onset @entity6 and their first-degree relatives with control families. Remarkably, we found lower iNKT cell numbers in @entity6 families, and we identified two iNKT cell populations in some of the families. One iNKT cell population expressed high iTCR levels (iNKT(hi)), whereas another expressed low levels (iNKT(lo)) and also expressed @entity8 . These findings support a probable genetic determinant of iNKT cell numbers and a possible role for these cells in @entity6 development. This study also suggests that @entity8 identifies recently activated iNKT lymphocytes.

title: Reduced iNKT cells numbers in type 1 XXXX @entity0 and their first-degree relatives.

answer: @entity1


abstract: @entity6 ( @entity6 ) is an @entity5 that is characterized by the specific destruction of insulin-producing pancreatic b cells. Invariant natural killer T (iNKT) cells have been associated with development of @entity6 . @entity8 ( @entity8 ) is expressed on activated iNKT, @entity4 (+), and @entity3 (+) T cells, and it is associated with the pro-inflammatory profiles of these cells. @entity9 gene expression in @entity7 (+) lymphocytes from non-obese @entity1 (NOD) @entity2 is associated with @entity6 onset. However, expression of @entity8 on T cells from @entity0 with @entity6 has not yet been evaluated. We compared iNKT cell ( @entity7 (+)Va24(+)Vb11(+)) numbers and @entity8 expression in a Mexican population with recent-onset @entity6 and their first-degree relatives with control families. Remarkably, we found lower iNKT cell numbers in @entity6 families, and we identified two iNKT cell populations in some of the families. One iNKT cell population expressed high iTCR levels (iNKT(hi)), whereas another expressed low levels (iNKT(lo)) and also expressed @entity8 . These findings support a probable genetic determinant of iNKT cell numbers and a possible role for these cells in @entity6 development. This study also suggests that @entity8 identifies recently activated iNKT lymphocytes.

title: Reduced iNKT cells numbers in type 1 @entity1 XXXX and their first-degree relatives.

answer: @entity0


abstract: BACKGROUND: Multicenter clinical trials have established that the adjunctive use of the subgingival controlled release of @entity3 , (CHX chip), significantly reduces @entity1 ( @entity1 ), improves clinical attachment levels, and reduces @entity2 on probing compared to scaling and root planing (SRP) alone for periods of up to 9 months. The present report is based on a phase IV clinical trial to examine the adjunctive use of the CHX chip for routine periodontal maintenance therapy (RPMT) over 2 years. METHODS: Eight hundred thirty-five (835) @entity0 were recruited into the study. At baseline a CHX chip was placed in pocket sites with @entity1 > or = 5 mm. The @entity0 were scheduled to receive RPMT at 3-month intervals with repeated CHX chip placement at sites where the @entity1 remained > or = 5 mm. @entity0 who did not attend the 24-month recall visit or who failed to attend 2 consecutive time frame examinations were excluded from the analyses. RESULTS: The 595 @entity0 included showed a continuous decrease in @entity1 over 2 years of 0.95 mm. After 2 years, 23.2% of @entity0 had at least 2 pockets showing a reduction in @entity1 of 2 mm or more and 58.9% of the sites had been reduced to a @entity1 of < 5 mm. Only 2.9% (n = 57) of the sites showed an increase in @entity1 of > or = 2 mm. Adverse events were mild to moderate in nature and resolved spontaneously without medication. CONCLUSION: The results of this Phase IV or follow-up trial indicate that the adjunctive use of the CHX chip is a clinically safe and effective treatment option for long-term management of @entity4 .

title: Probing depth changes following 2 years of periodontal maintenance therapy including adjunctive controlled release of XXXX .

answer: @entity3


abstract: OBJECTIVES: @entity3 is the most common lower respiratory tract disease among @entity0 and results in 35 admissions per 1000 @entity0 in Canada. We describe the epidemiology of @entity3 presentations to @entity1 ( @entity1 ) made by @entity0 (aged  <=2 years) in Alberta, Canada. METHODS: Provincial administrative databases were used to obtain all @entity2 encounters for @entity3 during April 1999 to March 2005. Information included demographics, @entity2 visit timing, and subsequent visits to non- @entity2 settings. Data analysis included summaries and standardized rates. RESULTS: There were 26,742 @entity2 visits for @entity3 made by 18,155 @entity0 . Most (74.9%) had only 1 @entity3 -related @entity2 visit; males (60.6% of @entity2 visits, 59.8% of @entity0 ) more commonly presented than females. The standardized rates increased from 23.2 to 46.7 per 1000 in 1999/2000 to 2000/2001 and decreased gradually to 38.8 per 1000 in 2004/2005. Of the total visits, 22.6% required hospitalization. In a discharged subset, 10.4% had a repeat @entity2 visit within 7 days. Most @entity0 (63.3%) had yet to have a non- @entity2 follow-up visit by 1 week; median time to the first follow-up was 18 days. CONCLUSIONS: @entity3 is a common presenting problem in Alberta @entity1 , and further study of these trends is required to understand variation in presentations. The important findings include different trends in rates for the first 3 years before a gradual decrease, disparities based on age, sex, and socioeconomic/cultural status, and the low rate of early follow-up. Targeted interventions could be implemented to reduce @entity3 -related hospitalizations.

title: Presentations of @entity0 to @entity1 in Alberta, Canada, for XXXX : a large population-based study.

answer: @entity3


abstract: OBJECTIVES: @entity3 is the most common lower respiratory tract disease among @entity0 and results in 35 admissions per 1000 @entity0 in Canada. We describe the epidemiology of @entity3 presentations to @entity1 ( @entity1 ) made by @entity0 (aged  <=2 years) in Alberta, Canada. METHODS: Provincial administrative databases were used to obtain all @entity2 encounters for @entity3 during April 1999 to March 2005. Information included demographics, @entity2 visit timing, and subsequent visits to non- @entity2 settings. Data analysis included summaries and standardized rates. RESULTS: There were 26,742 @entity2 visits for @entity3 made by 18,155 @entity0 . Most (74.9%) had only 1 @entity3 -related @entity2 visit; males (60.6% of @entity2 visits, 59.8% of @entity0 ) more commonly presented than females. The standardized rates increased from 23.2 to 46.7 per 1000 in 1999/2000 to 2000/2001 and decreased gradually to 38.8 per 1000 in 2004/2005. Of the total visits, 22.6% required hospitalization. In a discharged subset, 10.4% had a repeat @entity2 visit within 7 days. Most @entity0 (63.3%) had yet to have a non- @entity2 follow-up visit by 1 week; median time to the first follow-up was 18 days. CONCLUSIONS: @entity3 is a common presenting problem in Alberta @entity1 , and further study of these trends is required to understand variation in presentations. The important findings include different trends in rates for the first 3 years before a gradual decrease, disparities based on age, sex, and socioeconomic/cultural status, and the low rate of early follow-up. Targeted interventions could be implemented to reduce @entity3 -related hospitalizations.

title: Presentations of @entity0 to XXXX in Alberta, Canada, for @entity3 : a large population-based study.

answer: @entity1


abstract: OBJECTIVES: @entity3 is the most common lower respiratory tract disease among @entity0 and results in 35 admissions per 1000 @entity0 in Canada. We describe the epidemiology of @entity3 presentations to @entity1 ( @entity1 ) made by @entity0 (aged  <=2 years) in Alberta, Canada. METHODS: Provincial administrative databases were used to obtain all @entity2 encounters for @entity3 during April 1999 to March 2005. Information included demographics, @entity2 visit timing, and subsequent visits to non- @entity2 settings. Data analysis included summaries and standardized rates. RESULTS: There were 26,742 @entity2 visits for @entity3 made by 18,155 @entity0 . Most (74.9%) had only 1 @entity3 -related @entity2 visit; males (60.6% of @entity2 visits, 59.8% of @entity0 ) more commonly presented than females. The standardized rates increased from 23.2 to 46.7 per 1000 in 1999/2000 to 2000/2001 and decreased gradually to 38.8 per 1000 in 2004/2005. Of the total visits, 22.6% required hospitalization. In a discharged subset, 10.4% had a repeat @entity2 visit within 7 days. Most @entity0 (63.3%) had yet to have a non- @entity2 follow-up visit by 1 week; median time to the first follow-up was 18 days. CONCLUSIONS: @entity3 is a common presenting problem in Alberta @entity1 , and further study of these trends is required to understand variation in presentations. The important findings include different trends in rates for the first 3 years before a gradual decrease, disparities based on age, sex, and socioeconomic/cultural status, and the low rate of early follow-up. Targeted interventions could be implemented to reduce @entity3 -related hospitalizations.

title: Presentations of XXXX to @entity1 in Alberta, Canada, for @entity3 : a large population-based study.

answer: @entity0


abstract: 1. The clearance and elimination half-lives for i.v. doses of @entity4 were determined in 6 groups of 6 male CD @entity1 with no prior treatment, then again following 7 days treatment with graded oral doses of @entity3 , and finally after 3 i.p. doses of @entity2 . 2. Substantial increases in clearance and decreases in half-lives were observed following @entity2 treatment, demonstrating that @entity4 provides a reliable index of enzyme induction. 3. After treatment with @entity3 , maximal induction was seen in animals dosed at 27 or 80 mg/kg per day; an intermediate effect was found with 9 mg/kg per day and no effect at 0.2 and 1.0 mg/kg per day. 4. The results indicate that there is a substantial margin of safety between the proposed @entity0 therapeutic doses (7.5 to 15 mg/day) and the minimum effective dose that leads to enzyme induction in laboratory animals.

title: The effect of @entity3 administration on the pharmacokinetics of XXXX in the @entity1 .

answer: @entity4


abstract: 1. The clearance and elimination half-lives for i.v. doses of @entity4 were determined in 6 groups of 6 male CD @entity1 with no prior treatment, then again following 7 days treatment with graded oral doses of @entity3 , and finally after 3 i.p. doses of @entity2 . 2. Substantial increases in clearance and decreases in half-lives were observed following @entity2 treatment, demonstrating that @entity4 provides a reliable index of enzyme induction. 3. After treatment with @entity3 , maximal induction was seen in animals dosed at 27 or 80 mg/kg per day; an intermediate effect was found with 9 mg/kg per day and no effect at 0.2 and 1.0 mg/kg per day. 4. The results indicate that there is a substantial margin of safety between the proposed @entity0 therapeutic doses (7.5 to 15 mg/day) and the minimum effective dose that leads to enzyme induction in laboratory animals.

title: The effect of XXXX administration on the pharmacokinetics of @entity4 in the @entity1 .

answer: @entity3


abstract: 1. The clearance and elimination half-lives for i.v. doses of @entity4 were determined in 6 groups of 6 male CD @entity1 with no prior treatment, then again following 7 days treatment with graded oral doses of @entity3 , and finally after 3 i.p. doses of @entity2 . 2. Substantial increases in clearance and decreases in half-lives were observed following @entity2 treatment, demonstrating that @entity4 provides a reliable index of enzyme induction. 3. After treatment with @entity3 , maximal induction was seen in animals dosed at 27 or 80 mg/kg per day; an intermediate effect was found with 9 mg/kg per day and no effect at 0.2 and 1.0 mg/kg per day. 4. The results indicate that there is a substantial margin of safety between the proposed @entity0 therapeutic doses (7.5 to 15 mg/day) and the minimum effective dose that leads to enzyme induction in laboratory animals.

title: The effect of @entity3 administration on the pharmacokinetics of @entity4 in the XXXX .

answer: @entity1


abstract: BACKGROUND: Secreted protein acidic and rich in cystein ( @entity6 ) is a small extramatrix-associated protein. Its production increases during angiogenesis and enhances @entity5 ( @entity5 ) expression. The goal of this study was to show the clinical relevance of @entity6 and its relation to @entity5 expression in @entity4 @entity0 . METHODS: The authors investigated @entity6 mRNA expression in 48 tissue samples of @entity2 characterized by @entity5 mRNA expression in a Northern blot analysis. Western blot analysis and immunohistochemistry were also performed in @entity4 tissue samples. RESULTS: All 48 tissue specimens had high expression of @entity6 mRNA. Quantitative evaluation showed that high @entity6 mRNA was associated significantly with lymph node @entity1 (P = 0.05) and poorer prognosis (P = 0.025). Expression of @entity6 mRNA was associated significantly with @entity5 mRNA expression (R = 0.65; P < 0.01). Both @entity6 and @entity5 were immunolocalized intensely in @entity3 and stromal cells, whereas normal esophageal mucosa and submucosa did not express @entity6 . The 35-kilodalton cleaved @entity6 was detected in @entity4 tissue specimens by Western blot analysis and it was associated with @entity5 mRNA expression. CONCLUSIONS: In terms of clinical significance, @entity6 accumulation may reflect a functional correlation with @entity5 and the associated expression could play a key role in the progression of @entity4 .

title: Clinical significance of secreted protein acidic and rich in @entity4 and its relation to XXXX progression.

answer: @entity3


abstract: BACKGROUND: Secreted protein acidic and rich in cystein ( @entity6 ) is a small extramatrix-associated protein. Its production increases during angiogenesis and enhances @entity5 ( @entity5 ) expression. The goal of this study was to show the clinical relevance of @entity6 and its relation to @entity5 expression in @entity4 @entity0 . METHODS: The authors investigated @entity6 mRNA expression in 48 tissue samples of @entity2 characterized by @entity5 mRNA expression in a Northern blot analysis. Western blot analysis and immunohistochemistry were also performed in @entity4 tissue samples. RESULTS: All 48 tissue specimens had high expression of @entity6 mRNA. Quantitative evaluation showed that high @entity6 mRNA was associated significantly with lymph node @entity1 (P = 0.05) and poorer prognosis (P = 0.025). Expression of @entity6 mRNA was associated significantly with @entity5 mRNA expression (R = 0.65; P < 0.01). Both @entity6 and @entity5 were immunolocalized intensely in @entity3 and stromal cells, whereas normal esophageal mucosa and submucosa did not express @entity6 . The 35-kilodalton cleaved @entity6 was detected in @entity4 tissue specimens by Western blot analysis and it was associated with @entity5 mRNA expression. CONCLUSIONS: In terms of clinical significance, @entity6 accumulation may reflect a functional correlation with @entity5 and the associated expression could play a key role in the progression of @entity4 .

title: Clinical significance of secreted protein acidic and rich in XXXX and its relation to @entity3 progression.

answer: @entity4


abstract: BACKGROUND: The @entity1 and @entity8 Group B conducted a Phase II trial to evaluate the efficacy, @entity3 , and pharmacokinetics of @entity7 administered at a maximum dose density for @entity0 with chemotherapy-na  ve, advanced-stage @entity6 ( @entity6 ). METHODS: @entity0 with Stage IIIB/IV or recurrent @entity6 , a performance status (PS) score of 0-1, and no history of chemotherapy exposure were eligible. @entity7 , 150 mg/m(2), was administered over 3 hours during Weeks 1-6 of an 8-week cycle. Doses were modified for ANC < 1500/microL or for >or= Grade 2 @entity2 on the day of therapy. Treatment continued until @entity3 or disease progression. Pharmacokinetics were assessed at Weeks 1, 3, and 5 of Cycle 1. RESULTS: Thirty-eight @entity0 (median age, 64 years; range, 31-81 years) were treated. There were 21 males (PS = 0 for 17). Eleven @entity0 had received previous radiation, 2 had brain metastases, 25 had @entity5 , 23 had Stage IV disease, 6 had StageIIIB disease, and 9 had recurrent disease. Grade 3-4 @entity10 occurred in 39% of @entity0 . There were no deaths due to @entity3 . Grade 2 or 3 @entity2 occurred in 29% and 24% of @entity0 , respectively. Ten (27%) @entity0 had Grade 3 @entity11 ( @entity4 concentration > 250 mg/dL). There were 16 partial responses (42%; 95% confidence interval [CI], 26-59%). The median survival period was 12.3 months (95% CI, 7.9-19.6%), and the 1-year and 2-year survival rates were 52% (95% CI, 39-71%) and 26% (95% CI, 15-45%), respectively. @entity7 pharmacokinetics were consistent with published values and clearance was not induced. Older age and @entity11 were associated with greater @entity9 . CONCLUSIONS: @entity7 at 150 mg/m(2) per week x 6 every 8 weeks can be administered safely in the cooperative group setting. These Phase II data are comparable to those associated with combination therapy. The weekly dose-dense schedule may be more active than conventional schedules.

title: Weekly, high-dose @entity7 in advanced lung carcinoma: a phase II study with pharmacokinetics by the @entity1 and XXXX Group B.

answer: @entity8


abstract: BACKGROUND: The @entity1 and @entity8 Group B conducted a Phase II trial to evaluate the efficacy, @entity3 , and pharmacokinetics of @entity7 administered at a maximum dose density for @entity0 with chemotherapy-na  ve, advanced-stage @entity6 ( @entity6 ). METHODS: @entity0 with Stage IIIB/IV or recurrent @entity6 , a performance status (PS) score of 0-1, and no history of chemotherapy exposure were eligible. @entity7 , 150 mg/m(2), was administered over 3 hours during Weeks 1-6 of an 8-week cycle. Doses were modified for ANC < 1500/microL or for >or= Grade 2 @entity2 on the day of therapy. Treatment continued until @entity3 or disease progression. Pharmacokinetics were assessed at Weeks 1, 3, and 5 of Cycle 1. RESULTS: Thirty-eight @entity0 (median age, 64 years; range, 31-81 years) were treated. There were 21 males (PS = 0 for 17). Eleven @entity0 had received previous radiation, 2 had brain metastases, 25 had @entity5 , 23 had Stage IV disease, 6 had StageIIIB disease, and 9 had recurrent disease. Grade 3-4 @entity10 occurred in 39% of @entity0 . There were no deaths due to @entity3 . Grade 2 or 3 @entity2 occurred in 29% and 24% of @entity0 , respectively. Ten (27%) @entity0 had Grade 3 @entity11 ( @entity4 concentration > 250 mg/dL). There were 16 partial responses (42%; 95% confidence interval [CI], 26-59%). The median survival period was 12.3 months (95% CI, 7.9-19.6%), and the 1-year and 2-year survival rates were 52% (95% CI, 39-71%) and 26% (95% CI, 15-45%), respectively. @entity7 pharmacokinetics were consistent with published values and clearance was not induced. Older age and @entity11 were associated with greater @entity9 . CONCLUSIONS: @entity7 at 150 mg/m(2) per week x 6 every 8 weeks can be administered safely in the cooperative group setting. These Phase II data are comparable to those associated with combination therapy. The weekly dose-dense schedule may be more active than conventional schedules.

title: Weekly, high-dose @entity7 in advanced lung carcinoma: a phase II study with pharmacokinetics by the XXXX and @entity8 Group B.

answer: @entity1


abstract: BACKGROUND: The @entity1 and @entity8 Group B conducted a Phase II trial to evaluate the efficacy, @entity3 , and pharmacokinetics of @entity7 administered at a maximum dose density for @entity0 with chemotherapy-na  ve, advanced-stage @entity6 ( @entity6 ). METHODS: @entity0 with Stage IIIB/IV or recurrent @entity6 , a performance status (PS) score of 0-1, and no history of chemotherapy exposure were eligible. @entity7 , 150 mg/m(2), was administered over 3 hours during Weeks 1-6 of an 8-week cycle. Doses were modified for ANC < 1500/microL or for >or= Grade 2 @entity2 on the day of therapy. Treatment continued until @entity3 or disease progression. Pharmacokinetics were assessed at Weeks 1, 3, and 5 of Cycle 1. RESULTS: Thirty-eight @entity0 (median age, 64 years; range, 31-81 years) were treated. There were 21 males (PS = 0 for 17). Eleven @entity0 had received previous radiation, 2 had brain metastases, 25 had @entity5 , 23 had Stage IV disease, 6 had StageIIIB disease, and 9 had recurrent disease. Grade 3-4 @entity10 occurred in 39% of @entity0 . There were no deaths due to @entity3 . Grade 2 or 3 @entity2 occurred in 29% and 24% of @entity0 , respectively. Ten (27%) @entity0 had Grade 3 @entity11 ( @entity4 concentration > 250 mg/dL). There were 16 partial responses (42%; 95% confidence interval [CI], 26-59%). The median survival period was 12.3 months (95% CI, 7.9-19.6%), and the 1-year and 2-year survival rates were 52% (95% CI, 39-71%) and 26% (95% CI, 15-45%), respectively. @entity7 pharmacokinetics were consistent with published values and clearance was not induced. Older age and @entity11 were associated with greater @entity9 . CONCLUSIONS: @entity7 at 150 mg/m(2) per week x 6 every 8 weeks can be administered safely in the cooperative group setting. These Phase II data are comparable to those associated with combination therapy. The weekly dose-dense schedule may be more active than conventional schedules.

title: Weekly, high-dose XXXX in advanced lung carcinoma: a phase II study with pharmacokinetics by the @entity1 and @entity8 Group B.

answer: @entity7


abstract: OBJECTIVES: We investigated associations between radiographic evidence of nodal extracapsular extension ( @entity4 ) and outcomes for locally advanced head and neck @entity3 (LAHNC). MATERIALS AND METHODS: We conducted a single-institution retrospective study of 258 consecutive LAHNC @entity0 with accessible pretreatment contrast-enhanced neck CT scans, who completed definitive or adjuvant radiation therapy. All scans were reviewed by an expert head and neck radiologist for evidence of @entity4 . Kaplan-Meier and Cox regression multivariate analyses (MVA) were performed to evaluate the impact of @entity4 on @entity2 ( @entity2 ), progression free survival (PFS), distant control (DC), and locoregional control (LRC). RESULTS: One-hundred forty @entity0 were @entity4 -positive and 118 were @entity4 -negative. The @entity4 -positive cohort had more cN3 disease (11.6% vs. 0.8%) and heavier smoking histories (60.0% vs. 44.9% with    10-pack-years). The @entity4 -positive cohort had significantly worse 3-year @entity2 (64.3% vs. 82.8%, p=0.002), PFS (58.9% vs. 76.0%, p=0.001), DC (72.3% vs. 90.6%, p<0.001), and LRC (75.9% vs. 89.8%, p=0.002). On MVA, @entity4 independently predicted for worse @entity2 , PFS, DC, and LRC for LAHNC overall. On subset analysis of @entity1 , @entity4 was not a significant prognosticator. CONCLUSION: For all sites of LAHNC, except @entity1 , presence of @entity4 independently predicts for worse disease control and survival. Further studies are needed to validate these findings and demonstrate whether @entity4 may be considered for risk-stratifying @entity0 for clinical trial design and treatment decisions.

title: Prognostic value of radiographic extracapsular extension in locally advanced head and neck XXXX .

answer: @entity3


abstract: @entity1 pre-replicative genes are transcribed, by @entity0 RNA polymerase, in two alternative modes: an early mode and a middle mode. Middle mode transcription is under the control of at least one viral protein, pmotA. We have identified two additional viral genes, @entity4 and motC, that map in the dispensable region of the @entity1 genome, between genes 39 and 56. pmotB and pmotC are diffusible factors which provide an alternative to the @entity2 dependent mode of middle transcription of many @entity1 genes. Deletions of @entity4 and motC are in fact lethal only in combination with a @entity2 mutant. @entity4 controls one of the alternative modes of transcription of the @entity3 gene. When @entity2 or @entity4 are missing, transcription of @entity3 is quantitatively unaffected; when both are missing the transcription rate drops by about 75%. Control of transcription of the tRNA gene cluster is more complex. Transcription of subcluster 2 is maximally reduced (70%) only by deletions that, besides @entity4 , cut out an adjacent region. We guess that this adjacent region codes for an additional control element, which we call motC. The @entity4 gene is situated in a 750-base region between the left end-points of del(39-56)-1 and -4.

title: New control elements of XXXX pre-replicative transcription.

answer: @entity1


abstract: Obesity is known to predispose to @entity1 ( @entity1 ), a condition characterized by repeated episodes of @entity5 or @entity6 during sleep, due to the interruption of airflow through the nose and mouth. These episodes lead to the @entity9 and to decrease in oxyhaemoglobin saturation. @entity0 with massive @entity2 , with or without daytime @entity10 should be systematically screened for @entity1 , because many of them appear to be asymptomatic and unaware of their @entity6 . Polysomnography (PSG) in an attended hospital laboratory setting is the gold standard for the diagnosis of @entity1 . However portable recording devices can be used for screening with good sensibility and specificity, and even for diagnosis when the @entity1 index is high. However the final diagnosis can only be carried out in a sleep laboratory using PSG by highly-qualified personnel, because of the limitations of the portable recording device. There is a strong association between @entity1 and the risk of traffic accidents. It has been established that @entity1 affects quality of life. There is also increasing evidence that @entity1 is an independent risk factor for @entity7 . This has been successfully demonstrated for @entity4 by prospective studies. But the evidence remains weak for @entity8 , @entity3 or mortality. Treating @entity1 with continuous positive airway pressure (CPAP) is the treatment of choice. CPAP improves quality of life, driving simulator performance, blood pressure and sleepiness, as demonstrated by randomised placebo controlled trials. The majority of @entity1 @entity0 are currently not being offered diagnosis testing and treatment. It's a real challenge due to the epidemic increase of @entity2 prevalence. Portable recording devices could be available outside the sleep laboratory in nutrition department, where @entity11 is treated. This emphasizes the need for a real collaboration between these departments and sleep experts.

title: [How do you really know if the XXXX @entity0 has @entity6 ?].

answer: @entity2


abstract: Obesity is known to predispose to @entity1 ( @entity1 ), a condition characterized by repeated episodes of @entity5 or @entity6 during sleep, due to the interruption of airflow through the nose and mouth. These episodes lead to the @entity9 and to decrease in oxyhaemoglobin saturation. @entity0 with massive @entity2 , with or without daytime @entity10 should be systematically screened for @entity1 , because many of them appear to be asymptomatic and unaware of their @entity6 . Polysomnography (PSG) in an attended hospital laboratory setting is the gold standard for the diagnosis of @entity1 . However portable recording devices can be used for screening with good sensibility and specificity, and even for diagnosis when the @entity1 index is high. However the final diagnosis can only be carried out in a sleep laboratory using PSG by highly-qualified personnel, because of the limitations of the portable recording device. There is a strong association between @entity1 and the risk of traffic accidents. It has been established that @entity1 affects quality of life. There is also increasing evidence that @entity1 is an independent risk factor for @entity7 . This has been successfully demonstrated for @entity4 by prospective studies. But the evidence remains weak for @entity8 , @entity3 or mortality. Treating @entity1 with continuous positive airway pressure (CPAP) is the treatment of choice. CPAP improves quality of life, driving simulator performance, blood pressure and sleepiness, as demonstrated by randomised placebo controlled trials. The majority of @entity1 @entity0 are currently not being offered diagnosis testing and treatment. It's a real challenge due to the epidemic increase of @entity2 prevalence. Portable recording devices could be available outside the sleep laboratory in nutrition department, where @entity11 is treated. This emphasizes the need for a real collaboration between these departments and sleep experts.

title: [How do you really know if the @entity2 @entity0 has XXXX ?].

answer: @entity6


abstract: Obesity is known to predispose to @entity1 ( @entity1 ), a condition characterized by repeated episodes of @entity5 or @entity6 during sleep, due to the interruption of airflow through the nose and mouth. These episodes lead to the @entity9 and to decrease in oxyhaemoglobin saturation. @entity0 with massive @entity2 , with or without daytime @entity10 should be systematically screened for @entity1 , because many of them appear to be asymptomatic and unaware of their @entity6 . Polysomnography (PSG) in an attended hospital laboratory setting is the gold standard for the diagnosis of @entity1 . However portable recording devices can be used for screening with good sensibility and specificity, and even for diagnosis when the @entity1 index is high. However the final diagnosis can only be carried out in a sleep laboratory using PSG by highly-qualified personnel, because of the limitations of the portable recording device. There is a strong association between @entity1 and the risk of traffic accidents. It has been established that @entity1 affects quality of life. There is also increasing evidence that @entity1 is an independent risk factor for @entity7 . This has been successfully demonstrated for @entity4 by prospective studies. But the evidence remains weak for @entity8 , @entity3 or mortality. Treating @entity1 with continuous positive airway pressure (CPAP) is the treatment of choice. CPAP improves quality of life, driving simulator performance, blood pressure and sleepiness, as demonstrated by randomised placebo controlled trials. The majority of @entity1 @entity0 are currently not being offered diagnosis testing and treatment. It's a real challenge due to the epidemic increase of @entity2 prevalence. Portable recording devices could be available outside the sleep laboratory in nutrition department, where @entity11 is treated. This emphasizes the need for a real collaboration between these departments and sleep experts.

title: [How do you really know if the @entity2 XXXX has @entity6 ?].

answer: @entity0


abstract: OBJECTIVES: To study the importance of sensitisation to occupational allergens for the occurrence of @entity1 and @entity3 in bakers. METHODS: This is a nested clinical case-referent study of bakers based on a cohort of Swedish former bakery students. Cases were @entity2 ( n=25) or rhinitic bakers ( n=20). Randomly selected bakers ( n=44) were referents. All subjects underwent skin prick tests (SPTs) with common allergens, flours, fungal alpha-amylase and the storage mite L. destructor. Indices of airway @entity0 were assessed in serum and the nose. RESULTS: Seven of the @entity2 and eight of the rhinitics reported onset of disease during bakery work. Flour SPTs were positive in 43% of the @entity2 or rhinitics vs 16% of referents. The corresponding figures for alpha-amylase were 29%, 25%, and 7%. The odds ratio, adjusted for atopy, for an SPT positive to flour or alpha-amylase for @entity2 with onset during bakery work was 5.8 (95% confidence interval 1.1-32), and 2.6 (0.4-16) for the corresponding rhinitics. The positive predictive value of sensitisation to flour or alpha-amylase in relation to a clinical diagnosis of @entity1 or @entity3 was 71%. Sensitisation to L. destructor was rare. The indices of airway @entity0 were similar in cases and in referents. CONCLUSIONS: Bakers' @entity1 is associated with sensitisation to flour and/or alpha-amylase, atopy taken into account. A similar association was suggested in bakers' @entity3 . Indices of airway @entity0 were of low predictive value for detecting bakers' @entity1 or @entity3 in this study.

title: Sensitisation to occupational allergens in bakers' @entity1 and XXXX : a case-referent study.

answer: @entity3


abstract: OBJECTIVES: To study the importance of sensitisation to occupational allergens for the occurrence of @entity1 and @entity3 in bakers. METHODS: This is a nested clinical case-referent study of bakers based on a cohort of Swedish former bakery students. Cases were @entity2 ( n=25) or rhinitic bakers ( n=20). Randomly selected bakers ( n=44) were referents. All subjects underwent skin prick tests (SPTs) with common allergens, flours, fungal alpha-amylase and the storage mite L. destructor. Indices of airway @entity0 were assessed in serum and the nose. RESULTS: Seven of the @entity2 and eight of the rhinitics reported onset of disease during bakery work. Flour SPTs were positive in 43% of the @entity2 or rhinitics vs 16% of referents. The corresponding figures for alpha-amylase were 29%, 25%, and 7%. The odds ratio, adjusted for atopy, for an SPT positive to flour or alpha-amylase for @entity2 with onset during bakery work was 5.8 (95% confidence interval 1.1-32), and 2.6 (0.4-16) for the corresponding rhinitics. The positive predictive value of sensitisation to flour or alpha-amylase in relation to a clinical diagnosis of @entity1 or @entity3 was 71%. Sensitisation to L. destructor was rare. The indices of airway @entity0 were similar in cases and in referents. CONCLUSIONS: Bakers' @entity1 is associated with sensitisation to flour and/or alpha-amylase, atopy taken into account. A similar association was suggested in bakers' @entity3 . Indices of airway @entity0 were of low predictive value for detecting bakers' @entity1 or @entity3 in this study.

title: Sensitisation to occupational allergens in bakers' XXXX and @entity3 : a case-referent study.

answer: @entity1


abstract: BACKGROUND: Prognostic factors for @entity0 with soft-tissue @entity4 who are treated with conservative surgery and radiation are documented poorly. METHODS: The clinicopathologic features and disease outcome for 1225 @entity0 with @entity4 who were treated with conservative surgery and radiation were reviewed retrospectively. Actuarial univariate and multivariate statistical methods were used to determine significant prognostic factors for local control, metastatic recurrence, and disease specific survival. RESULTS: The median follow-up of surviving @entity0 was 9.5 years. The respective local control rates at 5 years, 10 years, and 15 years were 83%, 80%, and 79%. Factors predictive of local recurrence were positive or uncertain resection margins; @entity2 located in the head and neck and the deep trunk; presentation with local recurrence; @entity0 age > 64 years; malignant @entity3 , @entity8 . or @entity4 histopathology; @entity2 measuring > 10 cm in greatest dimension; and high pathologic grade. Freedom from @entity1 at 5 years, 10 years, and 15 years was 71%, 68%, and 66%, respectively. Factors that were predictive of metastatic recurrence were high @entity2 grade; large @entity2 size (> 5 cm); and @entity7 , @entity5 , @entity6 , or @entity4 . The respective disease specific survival rates at 5 years, 10 years, and 15 years were 73%, 68%, and 65%. Adverse factors for disease specific survival were high @entity2 grade; large @entity2 size (> 5 cm); @entity2 located in the head and neck and deep trunk; @entity5 , @entity4 , or clear cell @entity4 ; @entity0 age > 64 years; and positive or uncertain resection margins. CONCLUSIONS: Soft-tissue @entity4 comprises a heterogeneous group of diseases. Prognostic factors for local recurrence, metastatic recurrence, lymph node recurrence, disease free survival, and disease specific survival are different, and optimal treatment strategies need to take this complexity into account.

title: Prognostic factors for @entity0 with localized soft-tissue XXXX treated with conservation surgery and radiation therapy: an analysis of 1225 @entity0 .

answer: @entity4


abstract: BACKGROUND: Prognostic factors for @entity0 with soft-tissue @entity4 who are treated with conservative surgery and radiation are documented poorly. METHODS: The clinicopathologic features and disease outcome for 1225 @entity0 with @entity4 who were treated with conservative surgery and radiation were reviewed retrospectively. Actuarial univariate and multivariate statistical methods were used to determine significant prognostic factors for local control, metastatic recurrence, and disease specific survival. RESULTS: The median follow-up of surviving @entity0 was 9.5 years. The respective local control rates at 5 years, 10 years, and 15 years were 83%, 80%, and 79%. Factors predictive of local recurrence were positive or uncertain resection margins; @entity2 located in the head and neck and the deep trunk; presentation with local recurrence; @entity0 age > 64 years; malignant @entity3 , @entity8 . or @entity4 histopathology; @entity2 measuring > 10 cm in greatest dimension; and high pathologic grade. Freedom from @entity1 at 5 years, 10 years, and 15 years was 71%, 68%, and 66%, respectively. Factors that were predictive of metastatic recurrence were high @entity2 grade; large @entity2 size (> 5 cm); and @entity7 , @entity5 , @entity6 , or @entity4 . The respective disease specific survival rates at 5 years, 10 years, and 15 years were 73%, 68%, and 65%. Adverse factors for disease specific survival were high @entity2 grade; large @entity2 size (> 5 cm); @entity2 located in the head and neck and deep trunk; @entity5 , @entity4 , or clear cell @entity4 ; @entity0 age > 64 years; and positive or uncertain resection margins. CONCLUSIONS: Soft-tissue @entity4 comprises a heterogeneous group of diseases. Prognostic factors for local recurrence, metastatic recurrence, lymph node recurrence, disease free survival, and disease specific survival are different, and optimal treatment strategies need to take this complexity into account.

title: Prognostic factors for XXXX with localized soft-tissue @entity4 treated with conservation surgery and radiation therapy: an analysis of 1225 @entity0 .

answer: @entity0


abstract: BACKGROUND: Prognostic factors for @entity0 with soft-tissue @entity4 who are treated with conservative surgery and radiation are documented poorly. METHODS: The clinicopathologic features and disease outcome for 1225 @entity0 with @entity4 who were treated with conservative surgery and radiation were reviewed retrospectively. Actuarial univariate and multivariate statistical methods were used to determine significant prognostic factors for local control, metastatic recurrence, and disease specific survival. RESULTS: The median follow-up of surviving @entity0 was 9.5 years. The respective local control rates at 5 years, 10 years, and 15 years were 83%, 80%, and 79%. Factors predictive of local recurrence were positive or uncertain resection margins; @entity2 located in the head and neck and the deep trunk; presentation with local recurrence; @entity0 age > 64 years; malignant @entity3 , @entity8 . or @entity4 histopathology; @entity2 measuring > 10 cm in greatest dimension; and high pathologic grade. Freedom from @entity1 at 5 years, 10 years, and 15 years was 71%, 68%, and 66%, respectively. Factors that were predictive of metastatic recurrence were high @entity2 grade; large @entity2 size (> 5 cm); and @entity7 , @entity5 , @entity6 , or @entity4 . The respective disease specific survival rates at 5 years, 10 years, and 15 years were 73%, 68%, and 65%. Adverse factors for disease specific survival were high @entity2 grade; large @entity2 size (> 5 cm); @entity2 located in the head and neck and deep trunk; @entity5 , @entity4 , or clear cell @entity4 ; @entity0 age > 64 years; and positive or uncertain resection margins. CONCLUSIONS: Soft-tissue @entity4 comprises a heterogeneous group of diseases. Prognostic factors for local recurrence, metastatic recurrence, lymph node recurrence, disease free survival, and disease specific survival are different, and optimal treatment strategies need to take this complexity into account.

title: Prognostic factors for @entity0 with localized soft-tissue @entity4 treated with conservation surgery and radiation therapy: an analysis of 1225 XXXX .

answer: @entity0


abstract: @entity6 - and @entity7 -dependent antiplatelet antibodies are generally believed to bind to the membrane glycoprotein complex, GPIb/IX. However, we and others have found that some drug-dependent antibodies bind to platelets from @entity0 with the @entity4 which lack these glycoproteins. We therefore studied the reactions of a group of these antibodies with normal and @entity4 platelets and their membrane proteins. As indicated by rosette formation of the sensitized platelets around protein A-Sepharose beads, two @entity6 - and two @entity7 -dependent antibodies reacted with both normal and @entity4 platelets at a high (300 microM) concentration of drug. At a pharmacologic drug concentration (10 microM), all four antibodies reacted with normal platelets but only the two @entity6 -induced antibodies reacted with @entity4 platelets. Immunoprecipitation studies with solubilized, @entity5 -labelled normal platelets, at both high and low drug concentrations, showed that each of the four antibodies precipitated proteins corresponding to GPIb and @entity8 . Fainter bands corresponding to glycoproteins IIb and IIIa, which do not label well with @entity5 , were also detected. With radioiodinated normal platelets, it was found that each of the four antibodies was capable of precipitating @entity2 /IIIa, but only in the presence of drug. The four antibodies also promoted drug-dependent precipitation of @entity2 and @entity3 from lysates of radioiodinated @entity4 platelets. The two @entity6 -dependent antibodies precipitated these glycoproteins at both high and low drug concentrations, while the @entity7 -dependent antibodies reacted much more strongly at the higher drug concentration. Precipitation of GPIb/IX was not observed with BSS platelets. Absorption of a @entity6 -induced antibody with @entity4 platelets in the presence of drug eliminated its ability to precipitate @entity2 and @entity3 . However, the absorbed antibody retained the ability to precipitate GPIb from solubilized normal platelets. Thus, at least two drug-dependent antibodies were present, one specific for GPIb/IX and the other for @entity2 /IIIa. These findings indicate that @entity1 , in addition to the GPIb/IX complex, can serve as targets for drug-dependent antibodies in both intact and detergent-solubilized platelet preparations.

title: XXXX - and @entity7 platelet antibodies can react with @entity2 /IIIa.

answer: @entity6


abstract: @entity6 - and @entity7 -dependent antiplatelet antibodies are generally believed to bind to the membrane glycoprotein complex, GPIb/IX. However, we and others have found that some drug-dependent antibodies bind to platelets from @entity0 with the @entity4 which lack these glycoproteins. We therefore studied the reactions of a group of these antibodies with normal and @entity4 platelets and their membrane proteins. As indicated by rosette formation of the sensitized platelets around protein A-Sepharose beads, two @entity6 - and two @entity7 -dependent antibodies reacted with both normal and @entity4 platelets at a high (300 microM) concentration of drug. At a pharmacologic drug concentration (10 microM), all four antibodies reacted with normal platelets but only the two @entity6 -induced antibodies reacted with @entity4 platelets. Immunoprecipitation studies with solubilized, @entity5 -labelled normal platelets, at both high and low drug concentrations, showed that each of the four antibodies precipitated proteins corresponding to GPIb and @entity8 . Fainter bands corresponding to glycoproteins IIb and IIIa, which do not label well with @entity5 , were also detected. With radioiodinated normal platelets, it was found that each of the four antibodies was capable of precipitating @entity2 /IIIa, but only in the presence of drug. The four antibodies also promoted drug-dependent precipitation of @entity2 and @entity3 from lysates of radioiodinated @entity4 platelets. The two @entity6 -dependent antibodies precipitated these glycoproteins at both high and low drug concentrations, while the @entity7 -dependent antibodies reacted much more strongly at the higher drug concentration. Precipitation of GPIb/IX was not observed with BSS platelets. Absorption of a @entity6 -induced antibody with @entity4 platelets in the presence of drug eliminated its ability to precipitate @entity2 and @entity3 . However, the absorbed antibody retained the ability to precipitate GPIb from solubilized normal platelets. Thus, at least two drug-dependent antibodies were present, one specific for GPIb/IX and the other for @entity2 /IIIa. These findings indicate that @entity1 , in addition to the GPIb/IX complex, can serve as targets for drug-dependent antibodies in both intact and detergent-solubilized platelet preparations.

title: @entity6 - and @entity7 platelet antibodies can react with XXXX /IIIa.

answer: @entity2


abstract: @entity6 - and @entity7 -dependent antiplatelet antibodies are generally believed to bind to the membrane glycoprotein complex, GPIb/IX. However, we and others have found that some drug-dependent antibodies bind to platelets from @entity0 with the @entity4 which lack these glycoproteins. We therefore studied the reactions of a group of these antibodies with normal and @entity4 platelets and their membrane proteins. As indicated by rosette formation of the sensitized platelets around protein A-Sepharose beads, two @entity6 - and two @entity7 -dependent antibodies reacted with both normal and @entity4 platelets at a high (300 microM) concentration of drug. At a pharmacologic drug concentration (10 microM), all four antibodies reacted with normal platelets but only the two @entity6 -induced antibodies reacted with @entity4 platelets. Immunoprecipitation studies with solubilized, @entity5 -labelled normal platelets, at both high and low drug concentrations, showed that each of the four antibodies precipitated proteins corresponding to GPIb and @entity8 . Fainter bands corresponding to glycoproteins IIb and IIIa, which do not label well with @entity5 , were also detected. With radioiodinated normal platelets, it was found that each of the four antibodies was capable of precipitating @entity2 /IIIa, but only in the presence of drug. The four antibodies also promoted drug-dependent precipitation of @entity2 and @entity3 from lysates of radioiodinated @entity4 platelets. The two @entity6 -dependent antibodies precipitated these glycoproteins at both high and low drug concentrations, while the @entity7 -dependent antibodies reacted much more strongly at the higher drug concentration. Precipitation of GPIb/IX was not observed with BSS platelets. Absorption of a @entity6 -induced antibody with @entity4 platelets in the presence of drug eliminated its ability to precipitate @entity2 and @entity3 . However, the absorbed antibody retained the ability to precipitate GPIb from solubilized normal platelets. Thus, at least two drug-dependent antibodies were present, one specific for GPIb/IX and the other for @entity2 /IIIa. These findings indicate that @entity1 , in addition to the GPIb/IX complex, can serve as targets for drug-dependent antibodies in both intact and detergent-solubilized platelet preparations.

title: @entity6 - and XXXX platelet antibodies can react with @entity2 /IIIa.

answer: @entity7


abstract: Binding of monoclonal antibody @entity3 to western blots of @entity0 seminal plasma was employed to follow the fate of a seminal vesicle-specific antigen (SVSA) during semen liquefaction. Ejaculates from four vasectomized donors were collected in a manner to inhibit liquefaction or to allow liquefaction to proceed at room temperature. Aliquots of the liquefying seminal fluid were removed at specific time points and further liquefaction inhibited with @entity2 ( @entity1 ). Western blot analysis using monoclonal antibody @entity3 demonstrated that the SVSA epitope in all donors was located on multiple bands ranging in mass from 15-92 kDa in unliquefied ejaculates; immunoreactive peptides below 15 kDa were not detected. As early as 5 min post ejaculation, immunoreactive bands below 15 kDa were identified in liquefying samples. During the same time period (5 min), immunoreactive bands of 69-71 and 58 kDa could not be immunologically detected in liquefying samples. A decrease in immunoreactive staining of components higher molecular mass was accompanied by a concomitant increase in immunoreactive staining of intermediate and small molecular mass molecules during the first 2 h of liquefaction. After 8-24 h of liquefaction, two immunoreactive bands of 10.9 and 12.5 kDa predominated. Between 24 and 48 h, each donor's ejaculate demonstrated a common single immunoreactive band of 10.9 kDa. These results indicate that there is a rapid transformation in mass of the SVSA with major 69-71 and 58 kDa bands being converted to forms of lower mass within 5 min of ejaculation.

title: XXXX seminal vesicle-specific antigen during semen liquefaction.

answer: @entity0


abstract: 1 The mechanism of action of @entity4 was studied on freshly dispersed cells of the @entity0 anococcygeus using microelectrodes and patch pipettes. 2 Micro-ionophoretic application of @entity4 evoked reproducible depolarizations which were reduced or blocked by @entity3 (10(-7)-10(-6) M). The time courses of the responses to @entity1 and @entity4 were similar. 3 The reversal potential of the @entity4 -induced response was -3.8 mV and similar to the value (-6.2 mV) found for @entity1 . 4 During the response to @entity4 the membrane conductance was increased. At depolarized membrane potentials @entity4 evoked biphasic membrane responses suggesting an increase in two separate ionic conductances. 5 With patch pipettes in the whole-cell configuration under voltage-clamp, @entity4 produced an inward current at a holding potential of -50 mV. The inward current was associated with an increase in membrane conductance with an equilibrium potential of about 0 mV. 6 It is suggested that muscarinic receptors and adrenoceptors in the @entity0 anococcygeus may activate similar membrane conductances. The most prominent mechanism is an increase in @entity2 ion conductance.

title: Membrane mechanism associated with muscarinic receptor activation in single cells freshly dispersed from the XXXX anococcygeus muscle.

answer: @entity0


abstract: @entity11 lactoperoxidase (WBLPO) was purified with Amberlite CG-50 ( @entity12 form) resin, CM-Sephadex C-50 ion-exchange chromatography, and Sephadex G-100 gel-filtration chromatography from skimmed buffalo milk. The purity of the WBLPO was shown with @entity0 -PAGE. The R(z) (A(412)/A(280)) value for the WBLPO was 0.9. The optimum pH for the WBLPO was at 6.0. The K(m) value at optimum pH and 25 degrees C was 0.13 mM. The V(max) value at optimum pH and 25 degrees C was 5.3 micro mol/min per ml. The K(i) values for @entity1 , @entity2 , @entity4 ( @entity4 ), @entity3 , @entity5 , @entity6 ( @entity8 ), @entity7 ( @entity9 ), and @entity10 were 1.087, 0.364, 0.302, 0.459, 0.330, 0.126, 0.093, and 2.125 M, respectively. All the solvents showed competitive inhibition. The I(50) values of @entity1 , @entity2 , @entity4 , @entity3 , @entity5 , @entity6 , @entity7 , and @entity10 were 2.910, 0.942, 0.537, 1.320, 0.875, 0.470, 0.405, and 3.920 M, respectively. @entity10 , @entity1 , @entity3 , and @entity2 have been found to be very promising solvents for performing biocatalytic reactions with LPO in organic media.

title: Effects of the water-miscible organic solvents on lactoperoxidase purified from creek- XXXX milk.

answer: @entity11


abstract: The purpose of this study was to characterize the changes in postsynaptic potentials recorded in ankle extensor motoneurons resulting from activation of the sural nerve after spinal cord transection in the adult cat. Eight acute and nine chronic animals were spinalized at T12. Intracellular recordings from motoneurons innervating the triceps surae were performed. Sural nerve stimulation evoked complex synaptic potentials consisting of early and late components in all motoneurons. Early excitatory and inhibitory postsynaptic potentials (PSPs), as well as long latency excitatory postsynaptic potentials were recorded and averaged for assessment of @entity1 amplitude and duration. Early PSPs, both excitatory and inhibitory, were significantly larger in the motoneurons of @entity0 spinalized 4-6 months earlier. Central latency of excitatory potentials were similar in the two samples of motoneurons, but the central latency associated with the initial inhibitory @entity1 was significantly shorter in the recordings from motoneurons of chronic spinal @entity0 . In most recordings, an additional inhibitory @entity1 followed the initial excitatory @entity1 in motoneurons, and this secondary inhibitory @entity1 was similar in peak amplitude and duration in both samples of motoneurons. Also, a long latency excitatory @entity1 was recorded in a large percentage of motoneurons from both samples. This potential was typically of greater amplitude and longer duration in the motoneurons from chronic animals, when compared to recordings from acute animals. Although changes in amplitude and duration of @entity1 activity could be documented, there was no marked alteration in the frequency of occurrence of each @entity1 pattern recorded from the two preparations. This suggests that the synaptic pathways mediating the sural nerve reflexes have not qualitatively changed in the chronic spinal animal. The changes in amplitudes and durations of the PSPs in the chronic spinal cat indicate, however, that quantitative changes have occurred. The quantitative changes have probably occurred in the interneuronal networks activated by cutaneous nerve (sural) stimulation, since it was shown that only minor changes in motoneuron membrane properties could be recorded in these same chronic spinal animals.

title: Characterization of postsynaptic potentials evoked by sural nerve stimulation in hindlimb motoneurons from acute and chronic spinal XXXX .

answer: @entity0


abstract: Bilateral destruction of the @entity1 ventromedial hypothalamus (VMH) produces a syndrome characterized by @entity3 and @entity0 . In the present study we examined whether grafts of fetal hypothalamus could reverse the effects of this lesion. Three groups of adult @entity1 received bilateral electrolytic lesions of the VMH. The first group of animals was then implanted with embryonic day 14-16 hypothalamic tissue by stereotaxic injection into the lesion sites. The second series of animals received comparable-sized grafts from a variety of non-hypothalamic regions of the fetal CNS. The third group experienced similar VMH lesions but did not receive any tissue grafts. After surgery, body weight and food consumption were recorded daily for up to 8 weeks. These measures were compared with similar ones obtained from non-operated @entity1 . @entity3 and @entity0 were consistently observed in all of the lesioned animals not bearing transplants. An initial period of @entity2 was also observed in animals receiving hypothalamic grafts, but the duration of the 'dynamic' phase of this syndrome was reduced. Consequently, these graft recipients exhibited significantly less @entity2 . This depressed @entity2 , however, did not coincide with a statistically significant decrease in @entity3 . Transplantation of non-hypothalamic tissue also caused an attenuation of the VMH-lesion effect but this was more modest than that induced by homotopic grafts. The results of this experiment show that homotopic transplants can alter the dynamics of @entity2 induced by bilateral VMH lesions. However, lesion-induced @entity3 was not completely reversed in these grafted animals. The fact that other regions can exert a similar effect, though of lesser magnitude, suggests that a more general property of fetal CNS tissue may be involved.

title: Fetal hypothalamic brain grafts reduce the XXXX produced by ventromedial hypothalamic lesions.

answer: @entity0


abstract: OBJECTIVE: To prospectively assess the relation between carotid plaque characteristics and the development of new cerebral @entity1 ( @entity1 ) at MRI. METHODS: Fifty TIA/ @entity2 @entity0 with ipsilateral 30-69% carotid stenosis underwent MRI of the plaque at baseline. Total plaque volume and markers of vulnerability to @entity3 (lipid-rich necrotic core [LRNC] volume, fibrous cap [FC] status, and presence of intraplaque hemorrhage [IPH]) were assessed. All @entity0 also underwent brain MRI at baseline and after one year. Ipsilateral cerebral @entity1 were quantified with a semiautomatic method. RESULTS: Mean WML volume significantly increased over a one-year period (6.52 vs. 6.97 mm(3), P=0.005). WML volume at baseline and WML progression did not significantly differ (P>0.05) between @entity0 with 30-49% and @entity0 with 50-69% stenosis. There was a significant correlation between total plaque volume and baseline ipsilateral WML volume (Spearman   =0.393, P=0.005). There was no significant correlation between total plaque volume and ipsilateral WML progression. There were no significant associations between LRNC volume and WML volume at baseline and WML progression. WML volume at baseline and WML progression did not significantly differ between @entity0 with a thick and intact FC and @entity0 with a thin and/or ruptured FC. WML volume at baseline and WML progression also did not significantly differ between @entity0 with and without IPH. CONCLUSION: The results of this study indicate that carotid plaque burden is significantly associated with WML severity, but that there is no causal relationship between carotid plaque vulnerability and the occurrence of @entity1 .

title: Association between carotid plaque characteristics and cerebral XXXX : one-year follow-up study by MRI.

answer: @entity1


abstract: Thirty-seven @entity0 and twelve @entity0 who had been sexually abused at an average of 2.6 years previously were traced and reviewed. The nonoffending parents participated in a structured interview and the @entity0 were assessed using the Piers-Harris Self-Concept Scale and the Achenbach @entity0 Behavior Checklist. Each @entity0 was matched with a @entity0 not known to have been sexually abused and these control @entity0 underwent a similar psychological assessment. Interviews with the nonoffending parents found that 76% of the @entity0 were thought to be less confident than before, 30% had fewer friends, and 20% were more aggressive. Increased sexual awareness was noted in 24%. School teachers reported that 28% still had behavior problems, 17% had repeated a year at school, and a further 17% had deteriorated in their school work. The sexually abused @entity0 had significantly lower self-esteem than the control @entity0 . There was no difference in self-esteem between the control and the sexually abused @entity0 . There was a higher incidence of stranger assault in the @entity0 compared with the @entity0 . The @entity0 Behavior Checklist completed by the parents, the Teacher Report Form, and the Youth Self-Report of the @entity0 Behavior Checklist showed that a highly significant proportion of sexually abused @entity0 fell into the clinical range. @entity1 appears to have long-term adverse consequences for many of the victims. This may have implications for their ability to relate to others, for the adult friendships they will make, and eventually for the way they will relate to their own @entity0 .

title: Personality development following XXXX .

answer: @entity1


abstract: BACKGROUND: Plant apoplast is the prime site for signal perception and defense response, and of great importance in responding to environmental stresses. @entity1 ( @entity2 ) plays a pivotal role in determining the responsiveness of cells to stress. However, how the apoplast proteome changes under oxidative condition is largely unknown. In this study, we initiated a comparative proteomic analysis to explore @entity2 -responsive proteins in the apoplast of @entity3 seedling roots. METHODOLOGY/PRINCIPAL FINDINGS: 14-day-old @entity3 seedlings were treated with low concentrations (300 and 600   M) of @entity2 for 6 h and the levels of relative electrolyte leakage, @entity4 and @entity2 were assayed in roots. The modified vacuum infiltration method was used to extract apoplast proteins of @entity3 seedling roots, and then two-dimensional electrophoresis gel analysis revealed 58 differentially expressed protein spots under low @entity2 conditions. Of these, 54 were successfully identified by PMF or @entity0 / @entity0 as matches to 35 different proteins including known and novel @entity2 -responsive proteins. Almost all of these identities (98%) were indeed apoplast proteins confirmed either by previous experiments or through publicly available prediction programs. These proteins identified are involved in a variety of processes, including redox homeostasis, cell wall modification, signal transduction, cell defense and @entity5 metabolism, indicating a complex regulative network in the apoplast of seedling roots under @entity2 stress. CONCLUSIONS/SIGNIFICANCE: The present study is the first apoplast proteome investigation of plant seedlings in response to @entity2 and may be of paramount importance for the understanding of the plant network to environmental stresses. Based on the abundant changes in these proteins, together with their putative functions, we proposed a possible protein network that provides new insights into oxidative stress response in the @entity3 root apoplast and clues for the further functional research of target proteins associated with @entity2 response.

title: Comparative proteomics analysis of the root apoplasts of @entity3 seedlings in response to XXXX .

answer: @entity1


abstract: BACKGROUND: Plant apoplast is the prime site for signal perception and defense response, and of great importance in responding to environmental stresses. @entity1 ( @entity2 ) plays a pivotal role in determining the responsiveness of cells to stress. However, how the apoplast proteome changes under oxidative condition is largely unknown. In this study, we initiated a comparative proteomic analysis to explore @entity2 -responsive proteins in the apoplast of @entity3 seedling roots. METHODOLOGY/PRINCIPAL FINDINGS: 14-day-old @entity3 seedlings were treated with low concentrations (300 and 600   M) of @entity2 for 6 h and the levels of relative electrolyte leakage, @entity4 and @entity2 were assayed in roots. The modified vacuum infiltration method was used to extract apoplast proteins of @entity3 seedling roots, and then two-dimensional electrophoresis gel analysis revealed 58 differentially expressed protein spots under low @entity2 conditions. Of these, 54 were successfully identified by PMF or @entity0 / @entity0 as matches to 35 different proteins including known and novel @entity2 -responsive proteins. Almost all of these identities (98%) were indeed apoplast proteins confirmed either by previous experiments or through publicly available prediction programs. These proteins identified are involved in a variety of processes, including redox homeostasis, cell wall modification, signal transduction, cell defense and @entity5 metabolism, indicating a complex regulative network in the apoplast of seedling roots under @entity2 stress. CONCLUSIONS/SIGNIFICANCE: The present study is the first apoplast proteome investigation of plant seedlings in response to @entity2 and may be of paramount importance for the understanding of the plant network to environmental stresses. Based on the abundant changes in these proteins, together with their putative functions, we proposed a possible protein network that provides new insights into oxidative stress response in the @entity3 root apoplast and clues for the further functional research of target proteins associated with @entity2 response.

title: Comparative proteomics analysis of the root apoplasts of XXXX seedlings in response to @entity1 .

answer: @entity3


abstract: OBJECTIVE: Nowadays, microsurgical discectomy is being performed as an outpatient procedure. A retrospective chart review was done to document factors that delayed discharge or led to unanticipated admission. METHODS: After Institutional Review Board approval, the hospital medical records of 106 @entity0 who underwent microsurgical discectomy on an ambulatory basis were reviewed. All @entity0 were operated upon by a single surgeon at the Toronto Western Hospital. Perioperative data were collected on specifically designed data sheets. All anesthetic and surgical factors that affected discharge were noted. RESULTS: Of the 106 @entity0 reviewed, only six required unanticipated admission. Two @entity0 were admitted due to @entity4 and @entity5 , one due to severe @entity2 , one due to urinary retention and two were surgical causes (dural tear). Eight @entity0 had delayed discharge. Anesthesia causes were severe @entity4 , severe @entity2 , low @entity1 saturation, sore throat and @entity6 . Two @entity0 had surgical causes. The incidence of @entity7 was 9.4%. Eighty @entity0 (75.4%) complained of @entity2 in the postanesthesia care unit. Of these, 33.9% had @entity3 scale scores more than 6. CONCLUSION: Ambulatory lumbar microdiscectomy can be carried out as an ambulatory procedure with an acceptably low unanticipated admission rate (5.7%). The percentage of @entity0 with severe @entity4 (16%) and @entity2 (33.9%) is high. Adequate perioperative @entity2 management and effective control of @entity4 and @entity5 may further improve the @entity0 ' experience after anesthesia for ambulatory microdiscectomy.

title: @entity2 , @entity4 , XXXX and ocular complications delay discharge following ambulatory microdiscectomy.

answer: @entity5


abstract: OBJECTIVE: Nowadays, microsurgical discectomy is being performed as an outpatient procedure. A retrospective chart review was done to document factors that delayed discharge or led to unanticipated admission. METHODS: After Institutional Review Board approval, the hospital medical records of 106 @entity0 who underwent microsurgical discectomy on an ambulatory basis were reviewed. All @entity0 were operated upon by a single surgeon at the Toronto Western Hospital. Perioperative data were collected on specifically designed data sheets. All anesthetic and surgical factors that affected discharge were noted. RESULTS: Of the 106 @entity0 reviewed, only six required unanticipated admission. Two @entity0 were admitted due to @entity4 and @entity5 , one due to severe @entity2 , one due to urinary retention and two were surgical causes (dural tear). Eight @entity0 had delayed discharge. Anesthesia causes were severe @entity4 , severe @entity2 , low @entity1 saturation, sore throat and @entity6 . Two @entity0 had surgical causes. The incidence of @entity7 was 9.4%. Eighty @entity0 (75.4%) complained of @entity2 in the postanesthesia care unit. Of these, 33.9% had @entity3 scale scores more than 6. CONCLUSION: Ambulatory lumbar microdiscectomy can be carried out as an ambulatory procedure with an acceptably low unanticipated admission rate (5.7%). The percentage of @entity0 with severe @entity4 (16%) and @entity2 (33.9%) is high. Adequate perioperative @entity2 management and effective control of @entity4 and @entity5 may further improve the @entity0 ' experience after anesthesia for ambulatory microdiscectomy.

title: @entity2 , XXXX , @entity5 and ocular complications delay discharge following ambulatory microdiscectomy.

answer: @entity4


abstract: OBJECTIVE: Nowadays, microsurgical discectomy is being performed as an outpatient procedure. A retrospective chart review was done to document factors that delayed discharge or led to unanticipated admission. METHODS: After Institutional Review Board approval, the hospital medical records of 106 @entity0 who underwent microsurgical discectomy on an ambulatory basis were reviewed. All @entity0 were operated upon by a single surgeon at the Toronto Western Hospital. Perioperative data were collected on specifically designed data sheets. All anesthetic and surgical factors that affected discharge were noted. RESULTS: Of the 106 @entity0 reviewed, only six required unanticipated admission. Two @entity0 were admitted due to @entity4 and @entity5 , one due to severe @entity2 , one due to urinary retention and two were surgical causes (dural tear). Eight @entity0 had delayed discharge. Anesthesia causes were severe @entity4 , severe @entity2 , low @entity1 saturation, sore throat and @entity6 . Two @entity0 had surgical causes. The incidence of @entity7 was 9.4%. Eighty @entity0 (75.4%) complained of @entity2 in the postanesthesia care unit. Of these, 33.9% had @entity3 scale scores more than 6. CONCLUSION: Ambulatory lumbar microdiscectomy can be carried out as an ambulatory procedure with an acceptably low unanticipated admission rate (5.7%). The percentage of @entity0 with severe @entity4 (16%) and @entity2 (33.9%) is high. Adequate perioperative @entity2 management and effective control of @entity4 and @entity5 may further improve the @entity0 ' experience after anesthesia for ambulatory microdiscectomy.

title: XXXX , @entity4 , @entity5 and ocular complications delay discharge following ambulatory microdiscectomy.

answer: @entity2


abstract: OBJECTIVE: To determine the effect of sensory sparing in motor complete @entity0 with @entity2 ( @entity2 ) on completion of rehabilitation on neurologic, functional, and social outcomes reported at 1 year. DESIGN: Secondary analysis of longitudinal data collected by using prospective survey-based methods. SETTING: Data submitted to the National @entity2 Statistical Center Database. @entity0 : Of @entity0 (N=4106) enrolled in the model system with a motor complete injury (American @entity3 Association Impairment Scale [AIS] grade A or B) at the time of discharge between 1997 and 2007, a total of 2331 (56.8%) completed a 1-year follow-up interview (Form II) and 1284 (31.3%) had complete data for neurologic (eg, AIS grade, injury level) variables at 1 year. INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURES: AIS grade (A vs B) at 1 year, bladder management, hospitalizations, perceived health status, motor FIM items, Satisfaction With Life Scale, @entity1 , and social participation. RESULTS: Compared with @entity0 with AIS grade A at discharge, @entity0 with AIS grade B were less likely to require indwelling catheterization and be hospitalized and more likely to perceive better health, report greater functional independence (ie, self-care, sphincter control, mobility, locomotion), and report social participation in the first year postinjury. A greater portion of individuals with AIS grade B at discharge had improved neurologic recovery at 1 year postinjury than those with AIS grade A. Significant AIS group differences in 1-year outcomes related to physical health were maintained after excluding @entity0 who improved to motor incomplete status for only bladder management and change in perceived health status. This recognition of differences between @entity0 with motor complete injuries (AIS grade A vs B) has important ramifications for the field of @entity2 rehabilitation and research.

title: The impact of sacral sensory sparing in motor complete XXXX .

answer: @entity2


abstract: Adult @entity0 retina can express regeneration-associated characteristics after @entity4 , provided it is supplied with appropriate diffusible substances originating from media conditioned by regenerating fish optic nerves or by optic nerves of a newborn @entity0 [Hadani et al., Proc. Natl. Acad. Sci. U.S.A., 81 (1984) 7965; Schwartz et al., Science, 228 (1985) 600]. This was shown by applying the active substances to the injured axons in the form of 'wrap-around' implants, consisting of collagen-coated @entity3 tubes which had been soaked in the @entity1 ( @entity1 ). The regeneration-associated response was manifested biochemically and by sprouting of nerve fibers in culture. The present work provides morphological evidence that the implantation prolongs survival of ganglion cells and optic nerve fibers and induces @entity2 . Light microscopic analysis (using horseradish peroxidase (HRP) for labeling the fibers) revealed, 1 week following @entity4 , labeled fibers and ganglion cells in both the implanted and control (injured only or injured and implanted with collagen-coated @entity3 tubes free of @entity1 ) nerves. However, from the second week after the injury, distinct differences in the appearance of viable ganglion cells and labeled fibers, were seen between experimental and control preparations. In sections taken through the optic nerve, at the region distal to the site of injury, HRP-labeled fibers were seen in the experimental nerves 1 week, 2 weeks and to a significantly lesser extent 1 month after injury.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Morphological response of injured adult XXXX optic nerve to implants containing media conditioned by growing optic nerves.

answer: @entity0


abstract: @entity1 was the most commonly isolated pathogen in the Canadian Ward Surveillance Study 2007-2009 (3789 isolates). Susceptibility to @entity13 (34.1%), @entity3 (73.8%), @entity6 (78.4%), and @entity4 (78.8%) was lowest. Susceptibility was above 90% for meropenem (100%), @entity15 (99.9%), @entity10 - @entity14 (97.6%), @entity12 (96.9%), @entity11 (95.6%), @entity0 - @entity2 (94.9%), @entity7 (94.1%), @entity9 (92.3%), and @entity5 (90.8%). Over the study period, there was a significant reduction in susceptibility to @entity0 - @entity2 and @entity3 for urinary tract isolates. Inpatient status was associated with greater resistance to nearly all antimicrobials including greater multidrug resistance (MDR). Increasing age was associated with resistance to @entity8 , @entity7 , @entity10 - @entity14 , and MDR. Female gender was associated with susceptibility to @entity8 and @entity12 . In conclusion, greater antimicrobial resistance and MDR in @entity1 were observed in inpatients, males, and with increasing age. The deterioration of susceptibility to @entity3 continues with the greatest reduction in urinary isolates. Significant regional differences in resistance rates were apparent.

title: Analysis of 3789 in- and outpatient XXXX isolates from across Canada--results of the CANWARD 2007-2009 study.

answer: @entity1


abstract: Prolonged stress has been associated with altered synaptic plasticity but little is known about the molecular components and mechanisms involved in the stress response. In this study, we examined the effect of @entity1 ( @entity1 ) on the expression of genes associated with synaptic vesicle exocytosis in @entity0 prefrontal cortex and hippocampus. @entity0 were stressed daily using a 21day restraint stress paradigm, with durations of half an hour or 6h. RNA and protein were extracted from the same tissue sample and used for real-time quantitative polymerase chain reaction (real-time qPCR) and immunoblotting, respectively. Focusing on the SNARE complex, we investigated the expression of the SNARE core components @entity3 , @entity2 , and @entity5 at both transcriptional and protein levels. In addition, the expression of 10 SNARE regulatory proteins was investigated at the transcriptional level. Overall, the prefrontal cortex was more sensitive to @entity1 compared to the hippocampus. In prefrontal cortex, @entity1 induced increased mRNA levels of @entity5 , @entity4 , @entity3 , @entity6 , synaptotagmins I and III, and @entity7 , whereas @entity2 was down-regulated after @entity1 . Immunoblotting demonstrated equivalent changes in protein levels of @entity5 , @entity3 , and @entity2 . In hippocampus, we found increased mRNA levels of @entity5 and @entity8 and a decrease in @entity4 levels. Immunoblotting revealed decreased @entity5 protein levels despite increased mRNA levels. Changes in the expression of synaptic proteins may accompany or contribute to the morphological, functional, and behavioral changes observed in experimental models of stress and may have relevance to the pathophysiology of stress-related disorders.

title: Differential expression of synaptic proteins after XXXX in @entity0 prefrontal cortex and hippocampus.

answer: @entity1


abstract: Prolonged stress has been associated with altered synaptic plasticity but little is known about the molecular components and mechanisms involved in the stress response. In this study, we examined the effect of @entity1 ( @entity1 ) on the expression of genes associated with synaptic vesicle exocytosis in @entity0 prefrontal cortex and hippocampus. @entity0 were stressed daily using a 21day restraint stress paradigm, with durations of half an hour or 6h. RNA and protein were extracted from the same tissue sample and used for real-time quantitative polymerase chain reaction (real-time qPCR) and immunoblotting, respectively. Focusing on the SNARE complex, we investigated the expression of the SNARE core components @entity3 , @entity2 , and @entity5 at both transcriptional and protein levels. In addition, the expression of 10 SNARE regulatory proteins was investigated at the transcriptional level. Overall, the prefrontal cortex was more sensitive to @entity1 compared to the hippocampus. In prefrontal cortex, @entity1 induced increased mRNA levels of @entity5 , @entity4 , @entity3 , @entity6 , synaptotagmins I and III, and @entity7 , whereas @entity2 was down-regulated after @entity1 . Immunoblotting demonstrated equivalent changes in protein levels of @entity5 , @entity3 , and @entity2 . In hippocampus, we found increased mRNA levels of @entity5 and @entity8 and a decrease in @entity4 levels. Immunoblotting revealed decreased @entity5 protein levels despite increased mRNA levels. Changes in the expression of synaptic proteins may accompany or contribute to the morphological, functional, and behavioral changes observed in experimental models of stress and may have relevance to the pathophysiology of stress-related disorders.

title: Differential expression of synaptic proteins after @entity1 in XXXX prefrontal cortex and hippocampus.

answer: @entity0


abstract: @entity9 is a new antiarrhythmic drug with a dominant local anaesthetic action and an additional beta-sympathicolytic activity. In this study, the results of long-term treatment (8 months on average) obtained from 27 @entity0 with chronic @entity4 are reported. Before @entity9 , all @entity0 were treated unsuccessfully with @entity8 , @entity7 , @entity6 , combined @entity6 / @entity8 and @entity6 / @entity7 , and another two to six antiarrhythmic agents. Following @entity9 (300-600 mg/24 h), a substantial reduction in arrhythmic activity (greater than or equal to 80%; Lown classification less than or equal to II) was achieved in 21 cases. In 12 @entity0 , side effects ( @entity5 , @entity1 , @entity2 , dizziness and heartburn) were apparent. @entity9 had to be discontinued in five @entity0 , because of these side effects. At dosages greater than or equal to 450 mg/24 h, the PQ interval was significantly lengthened, and QRS duration prolonged. In one @entity0 , an @entity3 III degree developed. In another case, SGOT and SGPT increased significantly; this increase was reversed after the drug was discontinued. Despite these side effects, further clinical evaluation of the compound seems promising, as the antiarrhythmic potency of @entity9 is very strong and superior to that of @entity7 with respect to the required doses.

title: [Treatment of chronic XXXX with the new class Ic anti- @entity4 agent diprafenon--results of long-term therapy].

answer: @entity4


abstract: @entity9 is a new antiarrhythmic drug with a dominant local anaesthetic action and an additional beta-sympathicolytic activity. In this study, the results of long-term treatment (8 months on average) obtained from 27 @entity0 with chronic @entity4 are reported. Before @entity9 , all @entity0 were treated unsuccessfully with @entity8 , @entity7 , @entity6 , combined @entity6 / @entity8 and @entity6 / @entity7 , and another two to six antiarrhythmic agents. Following @entity9 (300-600 mg/24 h), a substantial reduction in arrhythmic activity (greater than or equal to 80%; Lown classification less than or equal to II) was achieved in 21 cases. In 12 @entity0 , side effects ( @entity5 , @entity1 , @entity2 , dizziness and heartburn) were apparent. @entity9 had to be discontinued in five @entity0 , because of these side effects. At dosages greater than or equal to 450 mg/24 h, the PQ interval was significantly lengthened, and QRS duration prolonged. In one @entity0 , an @entity3 III degree developed. In another case, SGOT and SGPT increased significantly; this increase was reversed after the drug was discontinued. Despite these side effects, further clinical evaluation of the compound seems promising, as the antiarrhythmic potency of @entity9 is very strong and superior to that of @entity7 with respect to the required doses.

title: [Treatment of chronic @entity4 with the new class Ic anti- XXXX agent diprafenon--results of long-term therapy].

answer: @entity4


abstract: Most @entity2 @entity0 are seen and treated exclusively by primary care clinicians. However, primary care @entity0 with @entity2 are often not adequately treated. The aims of this pilot study were to measure the impact of a @entity1 program on @entity0 outcome and clinician adherence to practice guidelines, measure the relationship of clinician adherence to @entity0 outcome, and explore the measurement of @entity0 adherence to clinician recommendations and its impact on @entity0 outcomes. Thirty-five primary care practices in the University of Pennsylvania Health System were randomized to @entity1 ( @entity1 ) or "usual care" (UC). All @entity0 received a baseline and a 16-week follow-up clinical evaluation performed over the telephone. Those from @entity1 practices also received follow-up contact at least every 3 weeks, with formal evaluations at weeks 6 and 12. These interval contacts were designed to facilitate @entity0 and clinician adherence to a treatment algorithm based on the Agency for Health Research and Quality (AHRQ) practice guidelines. @entity2 symptoms evaluated with the Community Epidemiologic Survey of @entity2 (CES-D) scale as well as guideline adherence were the primary outcome measures. Sixty-one @entity0 were enrolled in this pilot project. The overall effect for CES-D scores over time was significant, (P <.001), indicating that those participating in the trial (both @entity1 and UC groups) showed significant improvement. The interaction between intervention condition and time was also significant (P <.05), indicating that @entity1 @entity0 improved significantly more over time than did UC @entity0 . A greater proportion of @entity1 @entity0 had CES-D scores <16 by Week 16 (66.7 versus 33.3%; chi(2), P <.05). The improvement in @entity2 outcome for the @entity1 group was related to its impact on improving clinician adherence to @entity2 treatment algorithms. The @entity1 pilot did not show a statistically significant effect on improving @entity0 adherence to clinician recommendations, however. This preliminary data suggests that @entity1 for @entity2 improves both clinician guideline adherence and @entity0 outcomes in the acute phase of @entity2 . The effect on @entity0 outcome is at least partially explained by the effect of @entity1 on clinician adherence to @entity2 treatment algorithms.

title: The pilot study of a @entity1 program for XXXX .

answer: @entity2